Analyst Price Targets — SOPH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 26, 2026 2:36 pm | — | Guggenheim | $7.00 | $5.35 | TheFly | Sophia Genetics price target raised to $7 from $6 at Guggenheim |
| March 6, 2025 12:11 pm | — | BTIG | $5.00 | $3.11 | TheFly | Sophia Genetics price target lowered to $5 from $6 at BTIG |
| August 7, 2024 11:35 am | Tejas Savant | Morgan Stanley | $5.00 | $3.92 | TheFly | Sophia Genetics downgraded to Equal Weight from Overweight at Morgan Stanley |
| June 27, 2024 6:20 am | Subbu Nambi | Guggenheim | $6.00 | $4.52 | StreetInsider | Guggenheim Starts Sophia Genetics SA (SOPH) at Buy |
| January 3, 2023 7:14 am | Mark Massaro | BTIG | $6.00 | $2.06 | TheFly | Sophia Genetics initiated with a Buy at BTIG |
Latest News for SOPH
BOSTON and ROLLE, Switzerland, Feb. 25, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced that leadership will present at TD Cowen's 46th Annual Health Care Conference in Boston. Jurgi Camblong, Chief Executive Officer and co-founder of SOPHiA GENETICS, and Ross Muken, President of SOPHiA GENETICS, will participate in a fireside chat on Wednesday,…
BOSTON and ROLLE, Switzerland, Feb. 17, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the fourth quarter and full year 2025 before U.S. markets open on Tuesday, March 3, 2026. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning…
BOSTON and ROLLE, Switzerland, Feb. 10, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced the addition of two of the largest U.S. healthcare systems to its network. The two new institutions, which collectively analyze millions of genetic samples annually, include one of the leading nonprofit, multi-region integrated healthcare systems in the U.S.…
Precipio (NASDAQ: PRPO - Get Free Report) and SOPHiA GENETICS (NASDAQ: SOPH - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends. Institutional and Insider Ownership 10.5% of Precipio shares
SOPHiA GENETICS (NASDAQ: SOPH - Get Free Report) and Pulmonx (NASDAQ: LUNG - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership. Risk and Volatility SOPHiA GENETICS has a beta
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for SOPH.
Senate Trading
No Senate trades found for SOPH.
U.S. House Trading
No House trades found for SOPH.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.